Ionis (IONS) price target cut to $85 by Canaccord Genuity
Canaccord Genuity cut its Ionis Pharmaceuticals price target to $85.00 per share from $95.00, while maintaining a Buy rating, according to TradingView News.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.